Clinical trial
A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases
NCT07490951 is registered in ClinicalTrials.gov with Liang Zou as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases
- Lead sponsor
- Liang Zou
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- March 22, 2026
- Completion date
- December 31, 2029
- Enrollment
- 20 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.